- Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
- Antengene Presents Four Preclinical Posters at AACR 2024
- Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
- Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study
- Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia
- Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101 in Renowned Oncology Journal Cancer Research
- Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.86 |
---|---|
High | 0.95 |
Low | 0.85 |
Bid | 0.86 |
Offer | 0.89 |
Previous close | 0.87 |
Average volume | 297.80k |
---|---|
Shares outstanding | 674.89m |
Free float | 360.15m |
P/E (TTM) | -- |
Market cap | 587.15m HKD |
EPS (TTM) | -1.02 HKD |
Data delayed at least 15 minutes, as of Apr 25 2024 09:09 BST.
More ▼